Skip to main content

#156590

Anti-CD45 [OX29]

Cat. #156590

Anti-CD45 [OX29]

Cat. #: 156590

Unit size: 100 ug

Availability: 10-12 weeks

Target: CD45

Class: Monoclonal

Application: FACS

Reactivity: Rat

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: Medical Research Council; University of Oxford

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-CD45 [OX29]
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Rat
  • Host: Mouse
  • Application: FACS
  • Description: The antibody is directed against the leukocyte common antigen (L-CA), present on all leukocytes but not erythroid cells or cells from other tissues. The OX-29 competes for binding with OX-1 but recognises half the number of sites.
  • Immunogen: Rat lymph node cells and glycoproteins
  • Myeloma used: NS0/U
  • Recommended controls: IgG2a

Target Details

  • Target: CD45
  • Target background: The antibody is directed against the leukocyte common antigen (L-CA), present on all leukocytes but not erythroid cells or cells from other tissues. The OX-29 competes for binding with OX-1 but recognises half the number of sites.

Applications

  • Application: FACS

Handling

  • Format: Liquid
  • Unit size: 100 ug
  • Shipping conditions: Dry ice

References

  • Woollett et al. 1985. Eur J Immunol. 15(2):168-73. PMID: 2578966.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.